Lixte Biotechnology Holdings- Warrants (01/01/2025) Operating Income

The latest operating income for LIXTW is $-5.1B as of June 2026. That compares with $-3.1M in the prior-year period — down 165905.3% year over year. Investors often review this figure alongside Lixte Biotechnology Holdings- Warrants (01/01/2025)'s historical trend and sector peers before judging valuation or financial health.

Over the past year, LIXTW's operating income moved from $-3.1M to $-5.1B — a 165905.3% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Lixte Biotechnology Holdings- Warrants (01/01/2025)'s operating scale or balance-sheet position.

A operating income figure of $-5.1B for LIXTW is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting LIXTW's operating income ($-5.1B), review year-over-year change from $-3.1M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Lixte Biotechnology Holdings- Warrants (01/01/2025)'s operating income against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.